Volume : 13, Issue : 10, October – 2026
Title:
A CASE REPORT ON VALVULAR HEART DISEASE WITH ATRIAL FIBRILLATION
Authors :
Dr. GopalKumar Sunilkumar Singh, Roshinee.R, Dr Nagraj Hugar, Umaima Wasif , Amina Begum, Nadira Arjuman Sultana, Sania Khan, Cherka Swetha, Mohammed Ibrahim Mukri
Abstract :
Background: Valvular heart disease can cause cardiac changes, predisposing patients to atrial fibrillation (AF). AF may worsen symptoms and increase thromboembolic risk, making diagnosis and management important.
Case Presentation: A 62-year-old man presented with three months of exertional breathlessness, two months of palpitations and fatigue, and one month of bilateral pedal edema. Examination showed an irregularly irregular pulse, elevated JVP, crepitations, and a grade 3/6 pansystolic murmur at the apex. ECG confirmed AF with rapid ventricular response at 118 bpm. Echocardiography revealed grade III mitral regurgitation, left atrial enlargement (49 mm), mildly dilated left ventricle, and LVEF of 48%. Treatment with metoprolol, apixaban, furosemide, losartan, and atorvastatin improved symptoms and ventricular rate.
Conclusion: Recognition, anticoagulation, rate control, and congestion management can stabilize patients, while mitral regurgitation requires cardiology evaluation.
Keywords: Valvular heart disease, mitral regurgitation, atrial fibrillation, anticoagulation, echocardiography.
Cite This Article:
Please cite this article in press GopalKumar Sunilkumar Singh et al., A Case Report On Valvular Heart Disease With Atrial Fibrillation.,. Indo Am. J. P. Sci, 2026; 13(10).,
REFERENCES:
1. Zeng YI, Sun R, Li X, Liu M, Chen S, Zhang P. Pathophysiology of valvular heart disease. Exp Ther Med. 2016 Apr;11(4):1184-1188
2. Popa MO, Irimia AM, Papagheorghe MN, Vasile EM, Tircol SA, Negulescu RA, Toader C, Adam R, Dorobantu L, Caldararu C, Alexandrescu M, Onciul S. The mechanisms, diagnosis and management of mitral regurgitation in mitral valve prolapse and hypertrophic cardiomyopathy. Discoveries (Craiova). 2016 Jun 30;4(2):e61.
3. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res. 2017 Apr 28;120(9):1501-1517.
4. Castellá M. Atrial fibrillation surgery and mitral repair. J Vis Surg. 2017 Oct 28;3:150.
5. Dhont S, Bertrand PB, Erzeel J, Deferm S, Pison L, Vandervoort PM, Mullens W, Tang WHW, Martens P. The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial. Eur J Heart Fail. 2025 Aug;27(8):1500-1507.
6. Netala VR, Teertam SK, Li H, Zhang Z. A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. Cells. 2024 Sep 1;13(17):1471.
7. E Darby Md A. Management Of Atrial Fibrillation In Patients With Heart Failure. J Atr Fibrillation. 2014 Aug 31;7(2):1105.
8. Xiling Z, Puehler T, Sondergaard L, Frank D, Seoudy H, Mohammad B, Müller OJ, Sellers S, Meier D, Sathananthan J, Lutter G. Transcatheter Mitral Valve Repair or Replacement: Competitive or Complementary? J Clin Med. 2022 Jun 13;11(12):3377.
9. Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE, Keane MG, Silvestry FE. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. J Am Coll Cardiol. 2011 Sep 27;58(14):1474-81
10. Kato N, Ito J, Kaneko T, Hirose N, Amano M, Okada T, Sato Y, Ohno Y, Obokata M, Sato K, Watanabe H, Morita K, Machino-Ohtsuka T, Abe Y, Kagiyama N. Clinical Significance of Extreme Left Atrial Enlargement in Atrial Functional Mitral Regurgitation. Am J Cardiol. 2026 Jul 1;270:60-66.
11. Mesi O, Gad MM, Crane AD, Ramchand J, Puri R, Layoun H, Miyasaka R, Gillinov MA, Wierup P, Griffin BP, Kapadia SR, Harb SC. Severe Atrial Functional Mitral Regurgitation: Clinical and Echocardiographic Characteristics, Management and Outcomes. JACC Cardiovasc Imaging. 2021 Apr;14(4):797-808.
12. Hirji SA, Cote CL, Javadikasgari H, Malarczyk A, McGurk S, Kaneko T. Atrial functional versus ventricular functional mitral regurgitation: Prognostic implications. J Thorac Cardiovasc Surg. 2022 Dec;164(6):1808-1815.e4.
13. Dawwas GK, Barnes GD. Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease. Curr Cardiol Rep. 2022 Jun;24(6):731-738.
14. Melillo E, Rago A, Proietti R, Attena E, Carrella M, Golino P, D’Onofrio A, Nigro G, Russo V. Atrial Fibrillation and Mitral Regurgitation: Clinical Performance of Direct Oral Anticoagulants in a Real-World Setting. J Cardiovasc Pharmacol Ther. 2020 Nov;25(6):564-569.
15. Wagner CM, Brescia AA, Watt TMF, Bergquist C, Rosenbloom LM, Ceniza NN, Markey GE, Ailawadi G, Romano MA, Bolling SF; Michigan Mitral Research Group. Surgical strategy and outcomes for atrial functional mitral regurgitation: All functional mitral regurgitation is not the same! J Thorac Cardiovasc Surg. 2024 Feb;167(2):647-655.
16. Kim K, Kitai T, Kaji S, Pak M, Toyota T, Sasaki Y, Ehara N, Kobori A, Kinoshita M, Furukawa Y. Outcomes and predictors of cardiac events in medically treated patients with atrial functional mitral regurgitation. Int J Cardiol. 2020 Oct 1;316:195-202.